

## Special Issue

# Challenges and Future Trends of Hepatocellular Carcinoma Immunotherapy

### Message from the Guest Editors

Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide. Emerging immune checkpoint inhibitors (ICIs) have also made progress in HCC. ICIs alone as a first-line treatment have not achieved the desired effect; however, clinical trials evaluating combinatorial strategies involving ICIs and other anticancer agents, especially antiangiogenic agents, have produced more compelling results, marking a new era in HCC management. Combination therapy resulted in higher median overall survival (OS), median progression-free survival (PFS) benefit, and overall response rate (ORR). Atezolizumab-bevacizumab is also currently recognized as the new standard of care in front-line HCC and has been approved for use in several countries worldwide. Similarly, other combinations have been tested and are currently being evaluated. From this point of view, this Special Issue welcomes basic research, reviews, case reports, etc., on the current state of the art in the immunotherapy of HCC. Potential topics include, but are not limited to:

- Molecular experiments on novel immune-based combinations;
- Fighting resistance to immune checkpoint inhibitors;
- Biomarker-driven studies.

---

### Guest Editors

Dr. Angela Dalia Ricci

Medical Oncology Unit, National Institute of Gastroenterology, "Saverio de Bellis" Research Hospital, 70013 Castellana Grotte, Italy

Dr. Alessandro Rizzo

Struttura Semplice Dipartimentale di Oncologia Medica per la Presa in Carico Globale del Paziente Oncologico "Don Tonino Bello", I.R.C.C.S. Istituto Tumori "Giovanni Paolo II", 70124 Bari, Italy

---

### Deadline for manuscript submissions

closed (31 October 2023)



## International Journal of Molecular Sciences

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.9  
CiteScore 9.0  
Indexed in PubMed



[mdpi.com/si/135441](https://mdpi.com/si/135441)

*International Journal of  
Molecular Sciences*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[ijms@mdpi.com](mailto:ijms@mdpi.com)

[mdpi.com/journal/  
ijms](https://mdpi.com/journal/ijms)





# International Journal of Molecular Sciences

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.9  
CiteScore 9.0  
Indexed in PubMed



[mdpi.com/journal/  
ijms](https://mdpi.com/journal/ijms)



## About the Journal

### Message from the Editor-in-Chief

The *International Journal of Molecular Sciences (IJMS)* is an open access journal, which was established in 2000. The journal aims to provide a forum for scholarly research on a range of topics, including biochemistry, molecular and cell biology, and molecular biophysics. *IJMS* publishes both original research and review articles, and regularly publishes special issues to highlight advances at the cutting edge of research. We invite you to read recent articles published in *IJMS* and consider publishing your next paper with us.

---

### Editor-in-Chief

Prof. Dr. José L. Quiles  
Department of Physiology, Institute of Nutrition and Food Technology  
"Jose Mataix", Biomedical Research Center, University of Granada,  
Avda. Conocimiento s/n, 18100 Armilla, Granada, Spain

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, MEDLINE, Embase, CAPus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Biochemistry and Molecular Biology) / CiteScore - Q1 (Organic Chemistry)